Keros Therapeutics Reveals $5M Share Repurchase Authorization
Keros Therapeutics, Inc. ("Keros" or the "Company") (NASDAQ:KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of
Keros Therapeutics said it will buy back up to $5 million of its own stock—kind of like a company saying it believes in itself. When a company buys its own shares, it can be a sign the leaders think the stock is a good deal right now.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.